Pirfenidone and vitamin D mitigate renal fibrosis induced by doxorubicin in mice with Ehrlich solid tumor

Millon-Underwood, 2015, Exploratory study of breast cancer screening practices of urban women: a closer look at who is and is not getting screened, ABNF J., 26 Liu, 2006, Renal fibrosis: new insights into the pathogenesis and therapeutics, Kidney Int., 69, 213, 10.1038/sj.ki.5000054 Wang, 2000, Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events, Kidney Int., 58, 1797, 10.1046/j.1523-1755.2000.00342.x Ayla, 2011, 2011 Karaman, 2006, vol. 22, 428 Mohebbati, 2016, Adriamycin-induced oxidative stress is prevented by mixed hydro-alcoholic extract of Nigella sativa and Curcuma longa in rat kidney, Avicenna J. Phytomedicine, 6, 86 Yamashita, 2017, Podocyte-specific NF-κB inhibition ameliorates proteinuria in adriamycin-induced nephropathy in mice, Clin. Exp. Nephrol., 21, 16, 10.1007/s10157-016-1268-6 Heart, 2016, Mechanisms of doxorubicin toxicity in pancreatic β-cells, Toxicol. Sci., 152, 395, 10.1093/toxsci/kfw096 Macías-Barragán, 2010, The multifaceted role of pirfenidone and its novel targets, Fibrogenesis Tissue Repair, 3, 16, 10.1186/1755-1536-3-16 Kim, 2010, Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels, Invest. Ophthalmol. Vis. Sci., 51, 3061, 10.1167/iovs.09-4257 Pilz, 2011, vol. 58, 374 Mehrotra, 2009, vol. 76, 977 Ureña-Torres, 2011, vol. 58, 544 Schwarz, 1998, Effect of 1, 25 (OH) 2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats, Kidney Int., 53, 1696, 10.1046/j.1523-1755.1998.00951.x Tan, 2006, Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy, J. Am. Soc. Nephrol., 17, 3382, 10.1681/ASN.2006050520 Saleh, 2020, Pirfenidone and vitamin D ameliorate cardiac fibrosis induced by doxorubicin in Ehrlich ascites carcinoma bearing mice: modulation of monocyte chemoattractant protein-1 and Jun N-terminal kinase-1 pathways, Pharmaceuticals, 13, 348, 10.3390/ph13110348 Elhady, 2021, VEGFR-mediated cytotoxic activity of Pulicaria undulata isolated metabolites: a biological evaluation and in silico study, Life, 11, 759, 10.3390/life11080759 Minotti, 2004, vol. 56, 185 Polydorou, 2017, vol. 8, 24506 Arfian, 2016, Vitamin D attenuates kidney fibrosis via reducing fibroblast expansion, inflammation, and epithelial cell apoptosis, 62 Inc. CCG. Molecular operating environment (MOE), 2016 Khattab, 2021, Revisiting activity of some nocodazole analogues as a potential anticancer drugs using molecular docking and DFT calculations, Front. Chem., 9, 92, 10.3389/fchem.2021.628398 Samra, 2021, Bioassay-guided isolation of a new cytotoxic ceramide from Cyperus rotundus L, S. Afr. J. Bot., 139, 210, 10.1016/j.sajb.2021.02.007 Oza, 2012, Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas, J. Med. Chem., 55, 5130, 10.1021/jm300025r Lubkowski, 1997, The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions, Nat. Struct. Biol., 4, 64, 10.1038/nsb0197-64 Al-Karmalawy, 2021 Zaki, 2020, vol. 44, 16752 Al-Karmalawy, 2020, Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor, NJoC, 44, 13990, 10.1039/D0NJ02844D Alnajjar, 2020, Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease, 6 Eliaa, 2020, vol. 3, 1330 McConkey, 2002, The performance of current methods in ligand–protein docking, Curr. Sci., 845 Szalay, 2015, Oxidative/nitrative stress and inflammation drive progression of doxorubicin-induced renal fibrosis in rats as revealed by comparing a normal and a fibrosis-resistant rat strain, 10 Erkan, 2007, vol. 132, 1447 Morra, 2011, vol. 459, 465 Kozono, 2013 Trump, 2010, Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy, Cancer J. (Sudbury, Mass), 16, 1, 10.1097/PPO.0b013e3181c51ee6 Wickham, 2012, Cholecalciferol and cancer: is it a big D3-eal?, J. Adv. Pract. Oncol., 3, 249 Swami, 2000, 1α, 25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells, Clin. Cancer Res., 6, 3371 Zinser, 2005, 1, 24 (S)-Dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors, Anticancer Res., 25, 235 Hussein, 1997, vol. 15, 61 Omayma, 2011, vol. 1, 61 Rushendran, 2017, vol. 11, 66 Deman, 2001, vol. 16, 147 Zhao, 2015, vol. 2, 75 Sanchez-Niño, 2011, vol. 302 Tanios, 2012, vol. 2, 278 Cao, 2015, vol. 30, 183 Fernandes, 2015, vol. 71, 83 Riganti, 2006, vol. 119, 17 Szalay, 2015, Oxidative/nitrative stress and inflammation drive progression of doxorubicin-induced renal fibrosis in rats as revealed by comparing a normal and a fibrosis-resistant rat strain, PLoS One, 10, 10.1371/journal.pone.0127090 Luo, 2018, Schisandra chinensis lignans suppresses the production of inflammatory mediators regulated by NF-κB, AP-1, and IRF3 in lipopolysaccharide-stimulated RAW264, 7 Cells, 23, 3319 Guo, 2013, Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells, Cell. Physiol. Biochem., 32, 1668, 10.1159/000356602 Lawrence, 2009 Takakuta, 2010, vol. 629, 118 Nakanishi, 2004, vol. 41, 730 Inomata, 2014, vol. 15, 16 Guijarro, 2001, Transcription factor-κB (NF-κB) and renal disease, Kidney Int., 59, 415, 10.1046/j.1523-1755.2001.059002415.x Kim, 2013, Paricalcitol attenuates 4-hydroxy-2-hexenal-induced inflammation and epithelial-mesenchymal transition in human renal proximal tubular epithelial cells, 8 Klahr, 2000, The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease, Kidney Int., 57, S7, 10.1046/j.1523-1755.2000.07509.x Rodríguez-Peña, 2001, Up-regulation of endoglin, a TGF-β-binding protein, in rats with experimental renal fibrosis induced by renal mass reduction, Nephrol. Dial. Transplant., 16, 34, 10.1093/ndt/16.suppl_1.34 Yu, 2002, Therapeutic strategies to halt renal fibrosis, Curr. Opin. Pharmacol., 2, 177, 10.1016/S1471-4892(02)00144-3 Liu, 2010, vol. 21, 212 McCarty, 2006, vol. 67, 1277 López-Novoa, 2010, Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives, Therapeutics, 128, 61, 10.1016/j.pharmthera.2010.05.006 Elexpuru, 1997, Ehrlich ascites tumor cells produce a transforming growth factor-β (TGFβ)-like activity but lack receptors with TGFβ-binding capacity, Biochemistry C, 170, 153, 10.1023/A:1006809604193 Kalluri, 2010, vol. 120, 1786 Lan, 2011, vol. 7, 1056 Derynck, 2003, vol.425, 577 Lan, 2003, vol. 14, 1535 Meng, 2012, vol. 81, 266 Kim, 2017, 2017 Meng, 2016, vol. 12, 325 Gratia, 2012, Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress, Cardiovasc. Res., 95, 290, 10.1093/cvr/cvs134 Noble, 2011, Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials, Lancet, 377, 1760, 10.1016/S0140-6736(11)60405-4 Burghardt, 2007, Pirfenidone inhibits TGF-β expression in malignant glioma cells, Biochem. Biophys. Res. Commun., 354, 542, 10.1016/j.bbrc.2007.01.012 Cho, 2010, Pirfenidone: an anti-fibrotic therapy for progressive kidney disease, Expert Opin. Investig. Drugs, 19, 275, 10.1517/13543780903501539 Ma, 2014, Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents, Bioorg. Med. Chem. Lett., 24, 220, 10.1016/j.bmcl.2013.11.038 Li, 2017, vol. 22, 589 Park, 2010, vol. 77, 1076 Tan, 2006, 17, 3382 Ito, 2013, vol. 123, 4579 Ramirez, 2010, vol. 118, 142 Schwarz, 1998, vol. 53, 1696 Brogi, 2019 Elmaaty, 2021, Revisiting activity of some glucocorticoids as a potential inhibitor of SARS-CoV-2 main protease: theoretical study, RSC Adv., 11, 10027, 10.1039/D0RA10674G